Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of human interferon alpha-2b vaginal effervescent tablets as adjunctive therapy after physical removal of vaginal/cervical condyloma acuminatum
CTR20241695Phase 2Active
- Sponsor
- Beijing Kawin Technology Share-Holding Co., Ltd.
- Start
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of Anterferon in anogenital warts, sponsored by Beijing Kawin Technology Share-Holding Co., Ltd.. Started Jul 2024; status: active.
02
Drugs
Anterferon
03
Conditions
anogenital warts
Beyond the preview
Go deeper on CTR20241695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241695.